prgram v.16  

UAT Program  

Test

VAXX-Formal-Program 1 & 2  

Test

Test_Basrah  

UAT Program -BLL  

Program-Q  

The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease (LIBRA)

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD).Study details include:Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE …

UAT_Local 01-19-May  

This is for UAT_Local 01-19-May.

Dell study 2  

s

Formal Test 5  

Formal Test 5Formal Test 5Formal Test 5